RVL Pharmaceuticals plc

OTCPK:RVLP.Q Stock Report

Market Cap: US$111.0

RVL Pharmaceuticals Management

Management criteria checks 3/4

RVL Pharmaceuticals' CEO is Brian Markison, appointed in Jan 2016, has a tenure of 8.92 years. directly owns 2.1% of the company’s shares, worth $2.33. The average tenure of the management team and the board of directors is 8.9 years and 5.5 years respectively.

Key information

Brian Markison

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.9yrs
CEO ownership2.1%
Management average tenure8.9yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 16
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially

Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

May 13
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts

RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

May 12
RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares

RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Apr 20
RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt

Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

Jan 05
Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?

RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M

Oct 18

RVL Pharmaceuticals: Chapter 2 - A Developing Quandary

Sep 22

RVL Pharma in pact with Revision Skincare to broaden access to products

Aug 30

GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M

Aug 11

RVL Pharma posts preliminary 42% sales growth for eye treatment

Jul 07

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Jul 04
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture

Jun 15

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Apr 01
New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

RVL Pharmaceuticals: A Makeover For An Ugly Duckling

Mar 30

Osmotica: A Different Breed Of Cat

Dec 14

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Aug 20
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Osmotica: Paring Down, Focusing On UPNEEQ

Jul 16

CEO Compensation Analysis

How has Brian Markison's remuneration changed compared to RVL Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$525kUS$525k

-US$52m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$1mUS$665k

-US$83m

Sep 30 2021n/an/a

-US$115m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$82m

Dec 31 2020US$4mUS$716k

-US$89m

Sep 30 2020n/an/a

-US$64m

Jun 30 2020n/an/a

-US$178m

Mar 31 2020n/an/a

-US$285m

Dec 31 2019US$4mUS$683k

-US$271m

Sep 30 2019n/an/a

-US$351m

Jun 30 2019n/an/a

-US$243m

Mar 31 2019n/an/a

-US$112m

Dec 31 2018US$1mUS$633k

-US$110m

Sep 30 2018n/an/a

-US$1m

Jun 30 2018n/an/a

-US$10m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$1mUS$613k

-US$41m

Compensation vs Market: Insufficient data to establish whether Brian's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Markison (65 yo)

8.9yrs

Tenure

US$525,000

Compensation

Mr. Brian A. Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceutical Corp. since 2016. Mr. Markison had been an Operating Executive and Healthcare Industry Execu...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Markison
Chairman8.9yrsUS$525.00k2.1%
$ 2.3
James Schaub
Executive VP & COO8.9yrsUS$367.20k0.45%
$ 0.5
Christopher Klein
General Counsel11yrsUS$367.20k0.15%
$ 0.2
Michael DePetris
Principal Accounting Officer2.7yrsno datano data
Jarret Miller
Executive Vice President of Human Resources8.9yrsno datano data
Scott Schroppe
Secretaryno datano datano data

8.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: RVLP.Q's management team is seasoned and experienced (8.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Markison
Chairman8.9yrsUS$525.00k2.1%
$ 2.3
Gregory Cowan
Independent Director5.9yrsUS$234.00k0.045%
$ 0.05
Alisa Lask
Independent Director2.3yrsUS$159.94k0.020%
$ 0.02
Michael DeBiasi
Independent Director5.2yrsUS$309.10kno data

5.5yrs

Average Tenure

59yo

Average Age

Experienced Board: RVLP.Q's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 22:52
End of Day Share Price 2024/12/24 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RVL Pharmaceuticals plc is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
David SteinbergJefferies LLC
Glen SantangeloJefferies LLC